Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 oct. 2022 16h29 HE
|
Olema Oncology
SAN FRANCISCO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 16h30 HE
|
Olema Oncology
SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 sept. 2022 17h01 HE
|
Olema Oncology
SAN FRANCISCO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update
09 août 2022 16h35 HE
|
Olema Oncology
Received Fast Track designation from U.S. FDA for OP-1250 for the treatment of ER+/HER2- metastatic breast cancerReported progress across OP-1250 clinical development program, including selection of...
Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer
09 août 2022 16h30 HE
|
Olema Oncology
SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor...
Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference
04 août 2022 16h30 HE
|
Olema Oncology
SAN FRANCISCO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 août 2022 16h30 HE
|
Olema Oncology
SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer
21 juil. 2022 07h30 HE
|
Olema Oncology
SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S. Food and Drug Administration (FDA) has granted...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 juil. 2022 16h30 HE
|
Olema Oncology
SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program
09 juin 2022 07h35 HE
|
Olema Oncology
Favorable tolerability with no grade 3/4 neutropenia and encouraging anti-tumor activity across Phase 1b monotherapy expansionCombinability with CDK4/6i palbociclib demonstrated across initial dose...